Why the study?
Does CX-397 improve antithrombotic efficacy without increasing hemorrhagic risk compared to rHV-1, heparin, and argatroban in rat thrombosis models?
Does CX-397 improve antithrombotic efficacy without increasing hemorrhagic risk compared to rHV-1, heparin, and argatroban in rat thrombosis models?
CX-397 shows potent antithrombotic effects in rat models, particularly for platelet-dominant thrombosis, without increasing bleeding risk compared to rHV-1.
Answers are grounded in this paper and cite their sources.
Supports preclinical development of CX-397; leaves open translation to human antithrombotic use.
The novel recombinant hirudin analog CX-397 was investigated with respect to its pharmacological activity and antithrombin profiles in vivo and in vitro. In three different types of thrombosis models in rats, including stasis and thrombin-induced venous, glass surface-activated arterio-venous shunt, and ferric chloride-induced arterial thrombosis models, CX-397 and rHV-1 elicited potent antithrombotic effects, where the minimum effective doses of rHV-1 tended to be higher than those of CX-397 in the arterio-venous shunt and arterial thrombosis models. The hemorrhagic risk of CX-397 in template bleeding in rats was not higher than that of rHV-1, indicating that CX-397 is superior to rHV-1 for treating the platelet-dominant type of thrombosis. However, no differences were detected between CX-397 and rHV-1 in their effects on in vitro coagulation times and thrombin-induced platelet aggregation, suggesting the possibility that some unknown mechanisms other than simple thrombin inhibition are also involved in their antithrombotic actions.
No takes yet. Share an insight, caveat, or question.
A 1999 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: